SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins volatile consolidation after a rejected push toward recent highs is driving attention, with traders focused on whether it can reclaim resistance or lose support. Bulls view the pullback as a buying opportunity and anticipate another advance, while bears point to repeated rejections and warn of a deeper decline.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Reports that OpenAIs latest Ultrafast model uses Nvidia GPUs rather than Cerebras hardware, combined with staged post-IPO share unlocks and insider selling, are weighing on sentiment. Bears cite customer-concentration and share-supply risks, while bulls argue the broader OpenAI partnership and demand for AI inference remain intact.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendys sharp selloff and fresh-low discussion centers on major franchisee Meritages Chapter 11 filing and the outlook for its affected restaurants, alongside concerns about weak sales, franchise economics, and elevated food and operating costs. Bears see the episode as evidence of broader business stress, while bulls argue Wendys can take over or transfer the locations and improve their performance; short-squeeze and takeover hopes remain speculative.

Pump.fun

PUMP is drawing attention for a sharp rebound and bullish momentum, with traders pointing to improving chart patterns, buybacks and burns, and renewed activity in Solanas memecoin ecosystem. Enthusiasm over further gains is countered by traders calling the moves pump-and-dump behavior and questioning the rallys durability.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is drawing attention amid a price rebound and breakout talk, with traders pointing to increased JasmyChain activityincluding transactions using JASMY for gasand ecosystem developments such as Panasonic and AppBank collaborations. Bulls are accumulating and framing these as signs of growing utility, while skeptics question whether the activity will translate into adoption and remain concerned about exchange delistings.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings sharp selloff has traders focused on competition from Kalshi and Polymarket and uncertainty over the costs and regulation of its own prediction-market push. Bulls point to DKeXs reported volume growth and court rulings allowing states to regulate rivals, while bears worry that competition and investment spending will pressure market share and margins.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Evernorths approved merger and planned Nasdaq debut as XRPN, backed by a large XRP treasury, are dominating discussion, but XRP has stayed range-bound while XRPN rallied. Traders debate whether treasury demand and Ripples utility plans can support the token, versus concerns about escrow supply and persistently weak price action.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solanas price action is the main focus, with traders describing consolidation near resistance and watching for a breakout; bullish calls for a move higher compete with warnings that the rally could fade and crypto could sell off. Some traders also point to ETF inflows and staking as supportive themes, but the discussion is largely centered on technical levels and broader crypto-market direction.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs prolonged selloff is being tied to concerns about slowing growth and weaker U.S. engagement amid rising streaming competition, with managements comments about growth and bearish analyst views adding pressure ahead of earnings. Traders are divided: bears question the companys content and growth outlook, while bulls point to international growth and the lower valuation as reasons to accumulate.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL ovarian cancer cohort reported an estimated three-year overall survival rate of 48%, drawing attention to the possibility of durable benefit in a heavily pretreated population. Traders are optimistic that the data could strengthen the case for regulatory action, while others caution that the Phase 1b results come from a small, nonrandomized cohort and may not be enough to support approval.

statis crypto Watchlist

Ethereum

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$LXRX I am confused about the prospects for pilavadapin and will appreciate your enlightening comments.  My understanding is that the 10 mg dose shows statistically significant pain relief without disqualifying side effects in Phase II.  Phase III requires a financial partner but no commitment has been made while the company explores applications beyond DPNP.  If this is not the case, let me know what you think is actually happening.

Craig

kampo

StockTwits Web

Lexicon Pharmaceuticals Inc

 I am confused about the prospects for pilavadapin and will appreciate your enlightening comments.  My understanding is that the 10 mg dose shows statistically significant pain relief without disqualifying side effects in Phase II.  Phase III requires a financial partner but no commitment has been made while the company explores applications beyond DPNP.  If this is not the case, let me know what you think is actually happening.

Bryan Thomas

@Beebomb Not sure I accept that the LXRX is doing much (or enough to make a difference shorter term) as per ‘exploring applications beyond DPNP’.

I think most all are aware of the potential but the lack or progress could be LXRX wanting to be paid for this potential but big pharma potential partners are not willing to pay the asking price on unexplored applications.  

And, there is the rub.  

I also suspect it is difficult (for various reasons including off label uses, efficiency in testing, etc.) to have numerous partners; one for DPNP and others for the other potential applications.

My recommendations is for LXRX to accept a bit less upfront for licensing for all possible indications and make that up with a nicely tiered sales royalty so if Pilavapadin sells well among numerous applications, they still get paid.

Kareem Sanjaghi

StockTwits for iOS

 Not sure I accept that the LXRX is doing much (or enough to make a difference shorter term) as per ‘exploring applications beyond DPNP’.

I think most all are aware of the potential but the lack or progress could be LXRX wanting to be paid for this potential but big pharma potential partners are not willing to pay the asking price on unexplored applications.  

And, there is the rub.  

I also suspect it is difficult (for various reasons including off label uses, efficiency in testing, etc.) to have numerous partners; one for DPNP and others for the other potential applications.

My recommendations is for LXRX to accept a bit less upfront for licensing for all possible indications and make that up with a nicely tiered sales royalty so if Pilavapadin sells well among numerous applications, they still get paid.

Generic Poster

@Beebomb if you read between the lines (or the talk), they were not able to find a partner to fund th P3 trial. They are now talking new indications based on preclinical results. I think that this drug is dead for the time being. They are hitching their wagon to HCM. The potential approval of Zynquista for T1D would be a bonus. A license for HCM would like also drive scripts for Inpefs for HF. I also this the obesity Nova drug is a long shot.

 if you read between the lines (or the talk), they were not able to find a partner to fund th P3 trial. They are now talking new indications based on preclinical results. I think that this drug is dead for the time being. They are hitching their wagon to HCM. The potential approval of Zynquista for T1D would be a bonus. A license for HCM would like also drive scripts for Inpefs for HF. I also this the obesity Nova drug is a long shot.

James Stick

@Beebomb I think someone wants to buy these drugs at a flash sale. They want Lexicon to dissolve as a company and buy its assets. This is my opinion and not a fact.

 I think someone wants to buy these drugs at a flash sale. They want Lexicon to dissolve as a company and buy its assets. This is my opinion and not a fact.

Drex

@Beebomb I agree with some of these guys above.  They didn’t get a good offer period. They don’t want to admit it so they’re looking at other indications mostly as a way to avoid bad news.   

Right now I think it’s dead and priority is HCM followed by zynquista hope. 

We will see Pila pop up again if we get desperate for news.

 I agree with some of these guys above.  They didn’t get a good offer period. They don’t want to admit it so they’re looking at other indications mostly as a way to avoid bad news.   

Right now I think it’s dead and priority is HCM followed by zynquista hope. 

We will see Pila pop up again if we get desperate for news.

kevin hanks

@Beebomb The other unexplored explanation is that partnering with a partner could complicate any buy out talks with Novo. Could explain why the narrative went from we&#39;re talking to so many partners blah blah to crickets. My working theory is Novo is waiting on Zynquista FDA decision before they pull the trigger on the whole enchilada

Jack Vaughan

StockTwits For Android 

 The other unexplored explanation is that partnering with a partner could complicate any buy out talks with Novo. Could explain why the narrative went from we're talking to so many partners blah blah to crickets. My working theory is Novo is waiting on Zynquista FDA decision before they pull the trigger on the whole enchilada